|Theralase Technologies established incredible clinical results for cancer treatment in mice. Currenty the company has treated 6 human patients in a Phase II fully funded cancer study. If the phase I (completed human study) cancer treatment patients remain cancer free from a single treatment the company will have unpresidented data. The company is also advancing well toward the .60 price target set by Mackie Research. |
The clinical study of mice included...
Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment.
If Phase 1 patients went 2.5 years being cancer free, that would only capture 5% of the time the mice were cancer free.
Theralase Further Validates Anti-Cancer Memory Response
November 12, 2014
In research conducted at UHN in March 2012, mice were injected with 350,000 colon cancer cells (mouse cell line CT26.CL25) to produce cancerous tumours that were allowed to grow to approximately five millimeters in size. These tumours were treated with an injection of one of Theralase’s lead PDCs and then illuminated by Near Infrared (“NIR”) light to activate the PDC. The vast majority of tumours were completely destroyed. These mice were closely monitored for 20 months post treatment, until November 2013, where they remained cancer free.
In research conducted at UHN in May 2014, mice were again treated according to the March 2012 protocol and the mice who received the initial, successful Photo Dynamic Therapy (“PDT”) were re-injected with an equal number of colon cancer cells, 10 to 23 days later. With no further treatment intervention, 60% of the mice did not demonstrate tumour regrowth, while 40% had a small tumour regrowth, which was quickly destroyed. This raises the possibility of a short-term immune-mediated “memory response” that destroys cancer cells, with no further intervention.
In the research completed in November 2014, mice were again treated according to the March 2012 protocol and all of the mice who received the initial Photo Dynamic Therapy (“PDT”) were successfully treated and remained cancer free. These mice were then re-injected with an equal number of colon cancer cells 20 days later and with no further treatment intervention none of these mice demonstrated tumour regrowth. This confirms and further validates an ability to destroy the primary tumour and strongly suggests protection of the animal via the immune system leading to a short-term immune-mediated “memory response”.
The initial results in March 2012 and May 2014, have now been further validated by Theralase and UHN scientists this month, with a new set of animals confirming the immune-mediated “memory response”. This anti-cancer memory response suggests a major breakthrough in cancer research and may provide substantial treatment benefit and survival advantage to cancer patients. Technology that is able to rapidly and effectively destroy “patient-specific” cancer cells, prevent their recurrence and provide long lasting protection against local and distant metastasis, offers immense clinical benefit to cancer patients and the facilities that treat their disease.
Phase 1 (completed study) both patients 5 and 6 will be hitting 24 month treatment anniversary's. Both of these patients were cancer free 18 months after single treatment.
If both patients remain cancer free after 24 months from a single treatment, the company will have unprecedented data points.
Phase 1 patients 5 and 6 were respectfully initially treated on Jan 10 and Feb 7, 2018.
Theralase Technologies has a 256 per cent upside, says Mackie Research
September 20, 2019 by Nick Waddell